Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 2/20 | 0.43 |
| ▸ | MMP2 | P08253 | 6/20 | 0.37 |
| ▸ | MMP3 | P08254 | 4/20 | 0.37 |
| ▸ | MMP9 | P14780 | 4/20 | 0.37 |
| ▸ | MMP14 | P50281 | 4/20 | 0.37 |
| ▸ | MMP13 | P45452 | 2/20 | 0.37 |
| ▸ | MMP1 | P03956 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 2/20 | 0.33 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22459317 | 0.96 | RARB (0.40) | RARBMMP2MMP3MMP9MMP14 | |
| SCHEMBL22459597 | 0.92 | PPARG (0.39) | RARBMMP2MMP3MMP9MMP14 | |
| SCHEMBL22459380 | 0.90 | PPARG (0.41) | RARBPPARG | |
| SCHEMBL22459808 | 0.87 | TNKS2 (0.42) | PPARGMETAKR1B10AKR1B1 | |
| SCHEMBL22459369 | 0.87 | RARB (0.35) | RARBMMP2MMP3PPARGMET | |
| SCHEMBL22459336 | 0.87 | PPARG (0.39) | RARBPPARG | |
| SCHEMBL22459342 | 0.87 | POLB (0.41) | RARBPPARG | |
| SCHEMBL22459252 | 0.86 | LMNA (0.40) | RARBMETAKR1B10AKR1B1CTDSP1 | |
| SCHEMBL22459412 | 0.86 | LMNA (0.40) | RARBMETAKR1B10AKR1B1CTDSP1 | |
| SCHEMBL22561079 | 0.85 | LPAR1 (0.33) | RARBPPARGMETAKR1B10AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200299578-A1 | POLYMERIZABLE COMPOUND HAVING METHOXYMETHYL ACRYLIC GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2020-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299578-A1 | POLYMERIZABLE COMPOUND HAVING METHOXYMETHYL ACRYLIC GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, CCND1, CPNE4 | RARB 3668/4885MMP2 1874/4885MMP3 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.